A national-wide survey on clinical implementation of PGx testing into precision therapeutics for Chinese children: a long way before standard clinical practice

Wu, Wen-wen; Guo, Hong-Li; Li, Yue; Hu, Ya-Hui; He, Huan; Xu, Jing; Wang, Xiao-ling; Chen, Feng

doi:10.1186/s12913-024-11535-6

BMC Health Serv Res

2024

DOI: 10.1186/s12913-024-11535-6

|View full text |Cite

A national-wide survey on clinical implementation of PGx testing into precision therapeutics for Chinese children: a long way before standard clinical practice

Wen-wen Wu,

Hong-Li Guo,

Yue Li

et al.

Help me understand this report

View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Precision pharmacotherapy of atomoxetine in children with ADHD: how to ensure the right dose for the right person?

Guo,

Huang,

Wang

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Non-stimulant atomoxetine is recognized in various current clinical guidelines as an important alternative to stimulants for the pharmacological treatment of attention deficit/hyperactivity disorder (ADHD) in children. While its efficacy and tolerability for core symptoms are established, there is considerable inter-individual variability in response and exposure, highlighting the need for personalized dosing. In this review, we evaluated existing studies and summarized comprehensive evidence supporting the clinical implementation of therapeutic drug monitoring (TDM) and personalized dosing of atomoxetine, organized around a series of logically structured questions. Although there are notable gaps in achieving personalized dosing across multiple critical elements, the available evidence is helpful to endorse personalized dose adjustments based on TDM and CYP2D6 genotyping “whenever possible.” We advocate for ongoing improvement and enhancement in clinical practice. Future advancements will rely on a deeper understanding of ADHD, facilitating more precise diagnoses and personalized treatment strategies.

show abstract

Precision pharmacotherapy of atomoxetine in children with ADHD: how to ensure the right dose for the right person?

Guo,

Huang,

Wang

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

A national-wide survey on clinical implementation of PGx testing into precision therapeutics for Chinese children: a long way before standard clinical practice

Cited by 1 publication

References 35 publications

Precision pharmacotherapy of atomoxetine in children with ADHD: how to ensure the right dose for the right person?

Precision pharmacotherapy of atomoxetine in children with ADHD: how to ensure the right dose for the right person?

Contact Info

Product

Resources

About